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Mutations in cardiac sarcomere protein genes are associated with a variety of clinical phenotypes, including hypertrophic (HCM), dilated (DCM),
and restrictive (RCM) cardiomyopathy as well as left ventricular non-compaction, with the overlap of morpho-functional manifestations in
individual patients and families. Over time, initial phenotypes may undergo profound changes which determine clinical course and disease pro-
gression. Although genetic defects causing HCM and DCM have opposite effects at the myofilament level, a number of downstream maladaptive
mechanisms, ranging frommicrovasculardysfunctionand ischaemia tomyocardial fibrosis and fromdiastolic dysfunction toabnormal sympathetic
activation and arrhythmogenesis, seem to recur in sarcomeric cardiomyopathies, independent of the presenting phenotype. The extent and rate
at which each of these features occur and evolve may be radically different in each form of cardiomyopathy, determining a clinical heterogeneity
that is not only cross-sectional, but also longitudinal, i.e. time-related. Timely and sensitive detection of these long-term modifications in the clin-
ical setting is a key to preventing advanced disease and identifying novel therapeutic targets. The present review evaluates the contribution of
contemporary technology to pre-clinical diagnosis, characterization of phenotypes, and assessment of disease progression in sarcomere cardio-
myopathies, including echocardiography, positron emission tomography, magnetic resonance, pathology, and circulating biomarkers.
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This article is part of the Spotlight Issue on Sarcomeric cardiomyopathies: from bedside to bench and back.
1. Introduction
Mutations in cardiac sarcomere protein genes are associated with a con-
stellation of clinical phenotypes, whose heterogeneity contrasts sharply
with a stereotyped molecular basis (Figure 1 and Table 1). The most
common and best known form is represented by hypertrophic cardio-
myopathy (HCM), followed by dilated (DCM) and restrictive cardiomy-
opathy (RCM) as well as the more recently described left ventricular
non-compaction (LVNC) (Figure 1).1– 3 Sarcomere mutations causing
HCM and DCM have opposite functional effects at the myofilament
level (i.e. enhanced as opposed to reduced calcium sensitivity and
poweroutput, respectively); RCM appears at the genetic and biophysical
level to be within the spectrum of HCM, whereas LVNC is often asso-
ciated with LV remodelling and dysfunction resembling DCM.4 Although
eachof thesephenotypes is distinct andhasdifferent clinical implications,
there is an ampleoverlapofmorpho-functionalmanifestationsoccurring
within individual patients and families, which ultimately reflect the
common genetic background.4 Mixed phenotypes may occur because
different features are present from the initial development of disease,
as in the case of regional LVNC which may associate with virtually any
other cardiomyopathy. Alternatively, they may represent the final
result of long-term disease progression, as observed, for example, in
patients with the overlap HCM/RCM phenotype caused by troponin I
mutations, or in the rare end-stage HCM forms resembling DCM.
Over time, initial phenotypes undergo profound changes which deter-
mine clinical course and disease progression.5 A number of downstream
maladaptive features, ranging from the prolongation of cardiomyocyte
action potential to microvascular dysfunction, from intracellular calcium
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abnormalities to dysregulation of collagen turn-over, and from energetic
derangement to abnormal sympathetic activation, seem to recur in car-
diomyopathies caused by sarcomere gene mutations, although with
mechanisms which can be radically different based on the effects of the
causing gene defect and the presenting phenotype.6 The extent and the
rate at which each of these features occur and evolve are very variable
in each form of cardiomyopathy—and within individual patients—deter-
miningaclinicalheterogeneity that isnotonlycross-sectional, but also lon-
gitudinal, i.e. time-related. These manifestations suggest that sarcomere
gene mutations may act as strong disease drivers or modifiers, but that
their ultimate clinical expression is determined by a complex hierarchy
of genetic, epigenetic, and environmental factors.7
Understanding the long-term modifications of clinical phenotypes is a
key for the identification of disease mechanisms and the prevention of
disease progression. Constant advances in the epidemiology, clinical
characterization, imaging, and laboratory work-up have considerably
enriched our perception of cardiomyopathies, allowing increasing
confidence in the diagnosis of atypical phenotypes and improving our
acuity in detecting signs of deterioration. Aim of this work, largely focus-
ing on HCM, is to review the contribution of contemporary technology
to the characterization of phenotypes and the assessment of disease
progression. A detailed review of differential diagnoses of cardiomyop-
athies is beyond the scope of our work and has been exhaustively
addressed by recent consensus documents.8,9 Furthermore, indications,
methodologies, and interpretation of genetic testing in HCM are
reviewed in this issue by Ho et al.10 and in previous reviews on the
subject11,12 and will not be addressed in the present work.
2. Overview of clinical phenotypes
2.1 Hypertrophic cardiomyopathy
HCM was the first disease linked to sarcomere gene mutations, in 1990,
and has currently been associated with 1500 mutations in 11 genes
Figure 1 From genotype to phenotype and disease progression. Mutations in cardiac sarcomere protein genes are associated with distinct clinical phe-
notypes, classified as HCM, DCM, and RCM and LVNC. Sarcomere mutations causing HCM and DCM have opposite functional effects at the myofilament
level; RCM appears at the genetic and biophysical level to be within the spectrum of HCM, whereas LVNC is often associated with LV remodelling and
dysfunction resembling DCM. These four clinical entities share several downstream manifestations, ultimately crucial in determining clinical course and
outcome.
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encoding proteins of the thick and thin contractile myofilament compo-
nents or the adjacent Z-disc.10 It is the most common genetic heart
disease, characterized by complex pathophysiology, heterogeneous
morphology, and variable clinical manifestations over time.1,2,5 HCM is
defined by the presence of primary LV hypertrophy, not explained by
other cardiac or systemic conditions. Hypertrophy is typically regional
and asymmetric, usually involving the basal septum and anterior LV
wall, but developing in virtually all imaginable patterns and occasionally
involving the right ventricle and papillary muscles.13 Wall thickness
may vary abruptly in adjacent regions of the LV, and non-contiguous
hypertrophic segments separated by areas of normal thickness have
been described. In addition, the HCM phenotype is characterized by
the variable interplay of diastolic dysfunction, mitral valve and subvalvar
abnormalities, dynamic LV outflow and mid-ventricular obstruction,
right ventricular outflow obstruction, atrial remodelling, myocardial
crypts, bridging of the epicardial coronary arteries, apical aneurysms,
and autonomic nervous system abnormalities5 (Figures 2–5).
Genetic testing for HCM has been available for over two decades and
is now largely available following to the introduction of next-generation
sequencing.10,14 Despite early hopes that genotyping may prove useful
for the prediction of cardiac morphology and long-term outcome,
dedicated studies have failed to establish stringent relationships
between specific sarcomere myofilament genes, phenotype, and
outcome.11 Some generic genotype–phenotype correlations have
been identified: these include a particularly high yield of genotype-
positive individuals among patients with reverse septal curvature,15 ele-
vated penetrance and marked hypertrophy associated with MHY7
mutations, mild hypertrophy but enhanced arrhythmic propensity in
patients with TNNT2-related disease and early onset, marked diastolic
dysfunction and atypical localization of hypertrophy in thin filament
disease,16 severe phenotype and adverse outcome in patients with
complex genotypes featuring multiple mutations.17 Nevertheless, all
these principles are non-specific and have countless exceptions.10,11
In most patients, HCM affords normal longevity, with only mild symp-
tomsand stableclinical course.However, a life-long remodellingprocess
occurs within the myocardium which, in a substantial subset, leads to
clinical progression and may culminate in the so-called end-stage phase
in 5–7%.5,18 Four stages of disease have been proposed for clinical
and investigational purposes5 (Figure 2). (i) ‘Non-hypertrophic HCM’ is
a state characterized by the absence of LV hypertrophy in individuals har-
bouring HCM-causing mutations, investigated in the course of systematic
family screenings. Individuals in this stage are defined ‘genotype-positive/
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Pattern of inheritance, diagnostic yield, and causative genes associated with the four cardiomyopathy phenotypes
Clinical phenotypes Inheritance Genetic
heterogeneity
Diagnostic yield Causative genes
HCM Classical HCM phenotype
Syndromic HCM
AD.
AR, X-linked
mitochondrial (rare)
.10 genes
.1000 variants
40–65% Sarcomeric protein mutations:
MYBPC3;MYH7; TNNT2; TNNI3;
MYL2; TPM1; MYL3; ACTC1
Other: CSRP3; CAV3; JPH2; OBSCN;
ACTN2; MYH6; TTN; TNNC1;
Glycogen and lysosomal storage
diseases: PRKAG2; LAMP2 ; GLA; etc.
Infiltrative disorders: familial amyloidosis
(TTR, etc.)
Mitochondrial DNA
Syndromic HCM: PTPN11, FRDA, etc.
DCM DCM
Syndromic DCM
(with extracardiac phenotype)
AD.
AR, X-linked,
mitochondrial
(infrequent)
Genetic origin
20–35%
(higher in
syndromic)
.30 genes
.400 variants
20–30%, including
titin (higher in
syndromic)
Sarcomeric protein mutations: same as
HCM
Cytoskeletal genes: DMD; DES; VCL;
Sarcoglycan complex; Epicardin
EYA4
Z-band: MLP; TCAP
Nuclear membrane: LMNA; EMD.
Mitochondrial DNA
Intercalated disc protein mutations: JUP;
DSP;PKP2; DSG 2–3; DSC2; RyR2;
TGFb3
Other: TAZ, PSEN1–2; MYPN; NEXN ,
PLN
RCM Isolated RCM AD Genetic origin
possible
Unknown Sarcomeric protein mutations: same as
HCM (especially TNNI3 and MYH7)
Others: DES; TTR and APOE; HFE, DES
LVNC Isolated LVNC
Non-compaction in association
with other cardiomyopathic
phenotype
AD
X-linked
.7 genes
.20 variants
Low (15–25%) Sarcomeric protein mutations: same as
HCM
Other: LDB3, DTNA, TAZ
ACTC1 (actin); ACTN2 (a-actinin-2); APOE (apolipoprotein E); CSRP3 (Cysteine And Glycine-Rich Protein 3 - Cardiac LIM Protein); CRYAB (Crystallin, Alpha B chain); CAV3 (caveolin 3);
DMD (dystrophin); DES (desmin); DSG2–3 (desmoglein); DTNA (a-destrobrevin); DSC2 (desmocollin2); DSP (desmoplakin); EMD (emerin); FRDA (frataxin); GLA (alpha galactosidase);
HFE (haemochromatosis); JUP (plakoglobin); JPH-2 ( junctophilin-2); LAMP2 (lysosome-associated membrane protein2); LMNA (lamin A/C); LDB3 (LIM domain binding 3); MYBPC3
(myosin-binding protein C); MYH7 (beta myosin heavy chain);MYL2 (ventricular myosin regulatory light chain); MYL3 (ventricular myosin essential light chain); MLP (muscle LIM protein);
MYPN (myopalladin); MYH6 (a-myosin heavy chain); NEXN (nexilin).
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phenotype-negative’ (G+/Ph2). Nevertheless, subtle morphological ab-
normalities are often encountered in this group, consistent with subclin-
ical phenotypic expression. (ii) ‘Classic HCM phenotype’ is defined as the
phase in which the hypertrophy is fully developed and the LV is hyperdy-
namic—often promoting outflow obstruction—in the absence of signifi-
cant fibrotic changes. (iii) ‘Adverse remodelling’, occurring in 15% of
patients, is characterized by unfavourable structural modifications, super-
imposed to the ‘classic’ phenotype, translating into extensive LV fibrosis
and initial evidence of functional impairment (i.e. an LVEF in the low-
normal range of 50–65%), with preserved clinical and hemodynamic
balance. (iv) ‘Overtdysfunction’, occurring in5–7%ofpatients, character-
ized by severe functional deterioration of the LV (defined as overt systolic
dysfunction and/or restrictive pathophysiology), subtended by extreme
degrees of LV fibrosis and atrial dilatation, associated with haemodynamic
decompensation and adverse outcome. Rather than being an ‘average’
process, progression of HCM is a selective pathway followed by a
subset of HCM patients, which may occur at any age and lead to advanced
heart failure over years or decades.5,6,19
In paediatric patients, HCM recognizes more heterogeneous and
complex aetiologies compared with the adult population.20 In more
than 800 newly diagnosed children from the Pediatric Cardiomyopathy
Registry, HCM was associated with a malformation syndrome in 9%,
inborn errors of metabolism in 9%, and neuromuscular disorders in
8%.21 An aetiological diagnosis is clinically relevant in paediatric patients,
as outcome varies greatly by cause and age at diagnosis.22 Children with
HCM associated with an error of metabolism or malformation syn-
drome, both of which present at a younger age, had low 5-year survival
rates of 42 and 74%, respectively, when compared with 98% in those
with neuromuscular disorders, which normally present at an older
age. Among children with idiopathic HCM, 5-year survival was 94% for
those diagnosed after 1 year of age but only 82% for those diagnosed
before 1 year of age. Sudden death occurred in 44% of children diag-
nosed before 1 year of age but in all those diagnosed .1 year.21
2.2 Restrictive cardiomyopathy
In the spectrum of sarcomere diseases, a restrictive phenotype may re-
present the most advanced stageof disease progression in HCM patients
carrying mutations in thin filament protein genes16 or complex pheno-
types.5 However, a primary presentation as true RCM has been
described associated with Troponin I mutations, characterized by a
small LV with normal wall thickness, extreme diastolic dysfunction,
and marked bi-atrial dilatation.23 Idiopathic RCM is a rare entity, which
may present from infancy to late adulthood, often associated with
severe functional limitation and progressive clinical course leading to
heart failure-related death or cardiac transplantation.23–25 Outcome
is poor, especially in children, with a 5-year survival rate from diagnosis
around 65%.24– 26 Endomyocardial biopsy demonstrates non-specific
findings such as myocyte hypertrophy, interstitial fibrosis, and occa-
sionally endocardial fibrosis. The differential diagnosis of idiopathic
RCM includes infiltrative cardiomyopathies—particularly amyloidosis—
endomyocardial fibrosis and constrictive pericarditis.24
2.3 Dilated cardiomyopathy
In 2000, Kamisago et al.26 for the first time showed cosegregation for
mutations in b-myosin heavy chain and troponin T, in pedigrees with
DCM. Subsequent studies have repeatedly identified sarcomere gene
mutations in DCM families, as recently reviewed by McNally et al.27
Prior to the introduction of next-generation sequencing techniques,
sarcomere mutations have been identified in 25% of idiopathic
DCM cases26 and account for 10% of familial DCM.28 The most
common sarcomere genes identified in familial DCM are b-myosin
heavy chain (MYH7) (10%) and Troponin T (TNNT2) (3%), followed
by low-prevalence genes such as a-tropomyosin (TPM1), troponin C
(TNNC1), troponin I (TNNI3), and cardiac actin (ACTC).27,29 Auto-
somal recessive familial DCM has also been caused by mutations in
cardiac troponin I (TNNI3).30 Recently, next-generation sequencing
technology for the first time allowed to screen the giant sarcomeric
gene coding for titin (TTN). As a result, disruptive TTN mutations were
found in up to 25% of DCM index patients, changing this landscape sig-
nificantly.31 However, it remains to be established how TTN mutations
translate into disease, as many variants and even truncations may be
found also in healthy controls.
Clinically, DCM caused by sarcomere gene mutations is indistinguish-
able fromother formsof idiopathic DCMand lacks the ‘red flags’ found in
laminopathies and distrophin-related and mitochondrial disease, such as
elevated CK levels, skeletal muscle involvement, conduction blocks, or
hearing impairment.8 However, sarcomeric DCM may be suspected
based on age at presentation and long-term course. Specifically, presen-
tation early in life, from infancy to adolescence, is not uncommon and
associated with severe outcome including sudden cardiac death and
Figure 2 Stages of HCM. HCM is characterized by variable clinical
manifestations over time. Although HCM is usually not a progressive
disease and affords normal longevity, a life-long remodelling process
may occur within the myocardium, leading to severe LV dysfunction
in a minority of patients. Four stages of disease have been proposed
(see text for details). Thickness of the orange lines reflects prevalence
of each stage in HCM cohorts. LVEF indicates left ventricular ejection
fraction. Modified from Olivotto et al. Circ Heart Fail 2012;5:535–546.
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refractory heart failure, although striking improvement may be seen fol-
lowingappropriate treatment.32 Conversely, adult-onsetDCMof sarco-
meric origin tends to have a mild course observed and little tendency
towards progression.28,33,34 This clinical profile differs significantly from
that seen in other genetic causes of DCM, such as that caused by
lamin A/C or phospholamban mutations, which typically silent until
adulthood but associate with progressive course after their onset.35,36
Of note, DCM associated with TNNC1 and TNNT2 mutations seems
to be particularly severe and penetrant,33 a behaviour mirroring that
of thin filament-associated HCM and RCM.16
In subclinical DCM mutation carriers, subtle abnormalities in systolic
function have been described, despite normal left ventricular size and
systolic function.37 In contrast, mutations carriers in HCM families
exhibit evidence of impaired relaxation, in the absence of LV hyper-
trophy.38 These findings support the theory that the mutation’s intrinsic
impact on sarcomere function determines whether a dilated or hyper-
trophic phenotype will ultimately develop.
2.4 Left ventricular non-compaction
LVNC is characterized by prominent and diffuse trabeculation of the
LV alternating with deep intertrabecular recesses.39,40 These features
may be associated with other abnormalities such as LV dilatation and
systolic dysfunction or regional hypertrophy. The clinical course and
the outcome of LVNC remain unresolved, although progression to
advanced heart failure has been reported in patients with patients
with the DCM-like phenotype. Conversely, early concerns of enhanced
cardioembolic risk, due to thrombotic propensity of the intertrabecular
recesses, have not been confirmed in recent series.39 Mutations in
MYH7, ACTC, and TNNT2 have been associated with LVNC.41
As for HCM and DCM, however, there is no clear relation between
the type or location of the gene defects and resulting LVNC pheno-
type.42 Of note, LVNC is often detected in individuals with an otherwise
normal LVand seems to represent an accessory featureof all genetic car-
diomyopathies and other conditions such as congenital heart disease.
Thus, it is still debatedwhether it should be considereda separate clinical
and genetic entity or a non-specific morphological trait.8,39 The debate
has become exceedingly hard to solve, in view of the uncertainty sur-
rounding diagnostic criteria for LVNC. In the absence of a widely
accepted gold standard, a number of different criteria have been devel-
oped over the years, with little internal agreement. To date, there are
four echocardiographic and two magnetic resonance imaging (MRI)-
based approaches, which differ on the diagnostic ratio of compacted
to non-compacted myocardium and the timing of measurement (end-
systole or end-diastole).40 A consequence of this uncertainty is the
Figure 3 Different pathology findings of non-obstructive HCM. (A) Sudden death in a 15-year-old boy: short-axis view of the heart, showing massive LV
hypertrophy and a large white scar in the posteroseptal area. An intramyocardial course of the left anterior descending coronary artery is also visible. (B)
Heart transplant for end-stage systolic dysfunction. A 59-year-old male patient with a troponin T mutation: heart removed at transplantation with thinning
of basal and mid-ventricular septum (12 mm) compared with distal LV. (C ) Disarrayed cardiomyocytes associated with increased interstitial fibrosis, char-
acterized by strandsof collagen interlacing orenvelopingmyocardial fibres. (D) Replacement-type fibrosiswith collagen substituting myocyte loss (asterisk)
associated with medial remodelling and lumen narrowing of coronary arterioles (arrow). (Azan Mallory stain, original magnification 5×). (A) reprinted from
Basso et al. Hum Pathol 2000 with permission. (B) reprinted from Melacini et al. EHJ 2010 with permission.
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substantial risk of LVNC overdiagnosis in the general population, due to
the high prevalence of LV trabeculation which, however, seems to have
no clinical or prognostic relevance.42
3. Insights from pathology
Pathological studies on explanted and autopsy hearts have provided
important insights on the mechanisms underlying the clinical features
and natural history of cardiomyopathies and have provided the basis
for validation of tissue characterization by contemporary imaging
techniques. In clinical practice, pathological studies of myocardial
tissue are limited to patients undergoing surgery or endomyocardial
biopsy. Biopsies were routinely performed in the early days of cardiomy-
opathies, but their role in diagnosis and management has considerably
diminished following the advent of genetic testing and multimodality
imaging and is now largely confined to the differential diagnosis of
rare conditions (e.g. storage disease), evaluation of inflammatory/
autoimmune disease, or follow-up of transplanted patients.9
3.1 Hypertrophic and restrictive
cardiomyopathy
The distinctive macroscopic and histopatological features of HCM have
been thoroughly characterized (Figure 3). At the macroscopic level,
HCM is characterized by LV and/or right ventricular hypertrophy that
is usually, but not invariably, asymmetric and preferentially involves
the interventricular septum. Microscopic analysis shows hypertrophy
and spatial disorganization of myocardial fibres (‘disarray’) involving
fibre bundles or single myocytes. This is usually associated with
increased interstitial fibrosis, i.e. strands of collagen interlacing or envel-
oping myocardial fibres (Figure 3C). The degree of interstitial fibrosis
in HCM is greater than in secondary LV hypertrophy and thus likely
to represent a primary feature of disease.43 Furthermore, HCM is char-
acterized by replacement-type fibrosis, i.e. collagen fibres substituting
myocyte loss (Figure 3D), predominantly located in the mid-myocardium
of the regions with maximum wall thickness, suggesting a direct influence
of regional hypertrophy.44 Representation of replacement-type fibrosis
can vary profoundly, ranging from patchy microscopic scars to larger
spots, visible to the naked eye. Replacement-type fibrosis shows a
spatial relationship with remodelling of coronary arterioles (diameter
,100 mm), characterized by medial wall thickening due to smooth
muscle hypertrophy and increased collagen deposition, with variable
degrees of intimal thickening and perivascular fibrosis (Figure 3D), result-
ing in marked narrowing of the vessel lumen. This is in keeping with the
concept of an ischaemic origin of myocyte loss in HCM, supported by
clinical evidence of abnormal microvascular physiology.45 Alternative
mechanisms advocated for myocyte injury in HCM are energy depletion
leading to apoptosis and epicardial coronary artery disease, including
myocardial bridging.46,47
Figure4 MRI images showing rapid disease progression in a patient with HCM and complex genotype. In a 22-year-old malewith HCM caused by double
Myosin Binding Protein C3 mutation, MRI performed at the time of diagnosis in 2007 (A and C) and repeated after 2 years demonstrated marked increase in
LGE over time. A and B: four-chamber views; C and D: corresponding short-axis views.
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Figure 5 The broad spectrum of the echocardiographic phenotype. (A and B) Classic HCM phenotype. Parasternal long- (A) and short-axis (B) view
showing asymmetrical HCM in a 35-year-old female carrying the c.2864_2865delCT (p.Pro955Argfs) mutation in MyBPC3. (C) Left ventricular non-
compaction and intraventricular thrombosis. Apical three-chamber view showing LVNC (arrow) with a thrombus (star) in a 35-year-old male carrying
the c.1633G.A (p.Asp545Asn) and the c.2863G.A (p.Asp955Asn) mutations inMYH7. (D–F) HCM progression to end-stage. (D and E): adverse remod-
elling in a patient with HCM carrying the c.3133C.T (p.Arg1045Cys) in MYH7. This patient with a ventricular septum of 33 mm at baseline (D) showed LV
wall thinning and cavity dilatation during follow-up. At last evaluation (E), septal wall thickness was 17 mm, and end-diastolic diameter was 68 mm. (F):
parasternal long-axis view in a 37-year-old male with DCM associated with the c.2713T.C (p.Cys905Arg) mutation in MYH7. (G and H ) Obstructive
HCM. Continuous wave Doppler interrogation of the left ventricular outflow tract showing the absence of obstruction in resting condition (peak gradient
12 mmHg;G) but severe obstruction after provocation with the Valsalva manoeuvre (85 mmHg,H ). (I ) Strain values per segment during the heart cycle in a
normal heart and a patient with HCM. Ejection fraction was normal in both patients. The HCM patient showed regional decrease in peak systolic strain
compared with the normal control, most evident at the basal and mid-wall septal segments (green and white lines).
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Clinicopathological studies have identified the morphological sub-
strates of disease progression in HCM. Patients with systolic dysfunction
show extensive myocardial scarring, LV wall thinning, and chamber dila-
tation. In addition, heart failure mayoccur in the setting of severediastol-
ic impairment in patients with normal or mildly reduced ventricular
cavities, leading to a restrictive evolution, also characterized by diffuse
myocardial fibrosis. These pathological findings are also typical of
RCM associated with sarcomere mutations.23 Of note, however,
neither RCM nor restrictive HCM exhibit the extent of replacement-
type fibrosis or microvascular remodelling seen in the hypokinetic-
dilated form of HCM (Figure 3), suggesting a distinct pathogenetic
pathway. Rarely, a restrictive pathophysiology in HCM may be due to
massive LV hypertrophy leading to chamber obliteration, in the
absence of fibrotic changes.
Electrical instability can cause sudden arrhythmic death at any stage of
the natural history of cardiomyopathies. Pathology studies of young
HCM subjects dying suddenly almost invariably showed spots of
replacement-type fibrosis associated with acute and subacute myocar-
dial ischaemia.36 Grossly visible septal scars were observed in more
thanhalf of these patients, in keepingwith the hypothesis thatmyocardial
scarring is a pathological substrate for anisotropic re-entry. These scars
correlate with areas of late gadolinium enhancement (LGE) visualized
in vivo by MRI (Figure 4). However, other arrhythmic substrates include
the electrophysiological remodelling of the cardiomyocites,47 extensive
myocyte disarray,48 and in children, coronary myocardial bridging.49
3.2 Other cardiomyopathies
The pathology of DCM and LVNC has been reviewed elsewhere.50– 53
At present, distinctive pathological features are not recognized for
DCM and LVNC of sarcomeric aetiology. This is due to the lack of
studies specifically addressing the gross and microscopic findings of
this small subset of disease.
4. Insights fromelectrocardiography
Although not diagnostic per se, ECG abnormalities are very common in
patients with cardiomyopathies and their families, often leading to the
initial recognition of the disease, and may represent the only phenotype
in individuals with sarcomere gene mutations.8
4.1 Hypertrophic cardiomyopathy
In HCM cohorts, a normal ECG is present in less than 10% of patients,
generally associated with mild phenotype and favourable outcome.54,55
About 40% exhibit abnormalities which may raise the specific suspicion
of HCM, including Romhilt Estes point score ≥5, giant negative T wave
(typically associated with apical HCM), or a pathological inferolateral Q
wave,whereasover50%havenon-specificfindings suchas re-polarization
or intraventricularconductionabnormalities,whichmerely represent ‘red
flags’ for the identification of individuals deserving further investigation. In
one study, both a Romhilt Estes score≥5 and pathological Q waves were
associatedwithagreaterLVmass index,whereasgreaterLVwall thickness
values and Q waves were associated with the increased prevalence of
LGE.54 The presence of low voltages, pre-excitation, or atrioventricular
blocks may suggest alternative diagnoses such as cardiac amyloidosis,
mitochondrial, or storage disease. Rhythm disturbances such as atrial fib-
rillation and non-sustained ventricular tachycardia are common and have
important prognostic implication, the former with regard to disease pro-
gressionandheart failureand the latter forpredictionof suddendeath risk,
particularly in the young.56
4.2 Other cardiomyopathies
In sarcomere-related DCM patients, the ECG is generally non-specific,
with progressive left bundle branch block as the most common pattern.
The presence of distinct patterns such as posterior or posterolateral
infarct-likeorprogressiveatrioventricularconductiondelaypoint toalter-
native diagnoses such as distrophin-related disorders or laminopathies.8
In idiopathic RCM, the ECG is usually characterized by abnormalities
reflecting bilateral atrial enlargement, such as prominent and biphasic P
waves and atrial fibrillation. Non-specific findings resembling those of
HCM are also common, including a strain ST–T pattern, pathological
Q waves, and QT prolongation. However, unlike HCM, QRS duration
is usually normal. Paediatric patients with RCM may exhibit conduction
disturbances, such as PR prolongation and widening of the QRS, and are
at riskofdevelopinghigh-gradeAVblock, associated with sudden cardio-
vascular decompensation.57,58
In LVNC, the presence of an entirely normal ECG is rare, although
no specific ECG patterns have yet been identified. The most prominent
features are marked biventricular hypertrophy, ST elevation and T wave
abnormalities (isolated or diffuse T-wave inversion), intraventricular con-
duction delay, and re-polarization abnormalities. Notably, a Brugada-like
pattern has also been reported as a frequent feature of patients with
LVNC, although its prognostic implications are unresolved.59,60
5. Insights from echocardiography
Transthoracic echocardiography (TTE) is a quintessential tool for the
evaluation of patients with cardiomyopathies. Besides establishing
the diagnosis, TTE provides key morpho-functional information for
risk stratification, clinical decision-making, longitudinal follow-up,
and family screening programs.2 With the use of recently developed
techniques, assessing myocardial deformation, TTE constitutes a powerful
research tool providing insight into the pathophysiology of sarcomere-
related conditions (Figure 5).
5.1 Chamber morphology
End-diastolic LV cavity dimensions are generally normal or reduced in
HCM and RCM, and—by definition—increased in DCM. LV geometry
is altered in patients with cardiomyopathies, ranging from the spade-
shaped cavity of apical HCM (Figure 5A and B) to the spherical shape
of advanced DCM causing tethering of the mitral leaflets and functional
regurgitation. In LVNC, the LV wall has a typical spongy appearance, with
a thick non-compacted endocardial layer and a thin compacted epicar-
dial layer, exceeding a 2:1 ratio (Figure 5C).40 Contrast echocardiography
or MRI may be required to differentiate LVNC from apical HCM.59 Left
atrial enlargement is common in all sarcomere-related phenotypes, al-
though most striking in HCM and RCM. Antero-posterior LA diameter,
indexed volumes, and LA fractional shortening provide important prog-
nostic information in HCM, including risk of atrial fibrillation and long-
term outcome.61,62
5.2 LV hypertrophy
TTE is very accurate in measuring LV wall thickness, by virtue of its spatial
resolution and the capabilityof distinguishing the septum from fibromus-
cular paraseptal structures. Patients with DCM or RCM present with
normal LV wall thickness, whereas HCM is defined by values ≥15 mm
(or equivalent indexed to body size in children) ranging to ≥30 mm
(Figure 5A and B). Lesser values (12–14 mm) may be diagnostic in indivi-
duals with family history of HCM.1,2 In most patients, LV hypertrophy is
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preferentially located at the basal septum and anterior wall, but different
locations have been described such as the apex and lateral wall; in such
instances, MRI may prove more accurate than echocardiography in
defining LV morphology.13
5.3 LV function
Significant degrees of systolic dysfunction are associated with adverse
prognosis in all sarcomeric cardiomyopathies. A reduction in LVejection
fraction (LVEF) is the hallmark of DCM, but is also a feature of LVNC and
end-stage HCM (Figure 5D–F). When severe, it is always coupled with
marked diastolic dysfunction.5 Conversely, LVEF is usually preserved
in RCM and supernormal in classic HCM (with values .70%), although
indexes of longitudinal LV systolic function are impaired. Assessing dia-
stolic function in cardiomyopathies is challenging and, despite the wide
array of indexes developed over time, no single measure is considered
sufficiently accurate or comprehensive. The best estimate originates
from a combination of mitral inflow velocities, tissue Doppler Imaging,
pulmonary vein flow velocities, pulmonary artery systolic pressure,
and LA size.62 RCM is defined by the presence of extreme diastolic im-
pairment and severe outcome despite relatively preserved systolic func-
tion. In HCM and DCM, progression of diastolic dysfunction as part of
adverse remodelling over time is also related to adverse outcome,
particularly when a restrictive LV filling pattern becomes evident.5
5.4 Outflow tract obstruction
Dynamic LV outflow obstruction at rest is found in 25% of HCM
patients.63–66 In an additional proportion close to 40%, a gradient
≥50 mmHg can be elicited with exercise. Thus, symptomatic HCM
patients without obstruction at rest should be tested for dynamic ob-
struction using TTE during provocative manoeuvres such as Valsalva
or, ideally, physiological exercise. Conversely, pharmacological provo-
cation with dobutamine or amyl nitrite are not recommended due to
high false-positive rates.66 LV outflow obstruction is a major determin-
ant of symptoms and is associated with increased risk of heart
failure-related complications and death.64 It is classically due to mitral
systolic anterior motion (SAM) causing systolic septal contact and oblit-
erating the outflow tract64 (Figure 5). SAM is produced by drag forces
deriving from high velocity, abnormally directed anterograde systolic
flow within the LV, and is responsible for loss of leaflet coaptation and
mitral regurgitation associated with obstruction.65 Several anatomical
and pathophysiological mechanisms predispose to SAM. Importantly,
anomalies of the mitral valve and subvalvular apparatus, such as leaflet
elongation, anterior displacement of the papillary muscles, and direct in-
sertionof papillarymuscles into the anterior leaflet, are frequent in HCM
patients. Finally, HCM patients may be also characterized by LV mid-
ventricular and right ventricular outflow obstruction.9
5.5 Myocardial deformation
Recently introduced, two-dimensional tissue tracking allows the
measurement of myocardial velocity and the assessment of longitudinal,
circumferential, and rotational myocardial displacement. In HCM,
reduced longitudinal systolic strain and the strain rate are seen in hyper-
trophic regions, even though global contraction is normal or even
enhanced (Figure 5I).67 This pattern seems to differ from that observed
in other causes of myocardial hypertrophy and might be helpful in differ-
ential diagnosis. Echocardiographic analysis using tissue Doppler and
strain rate imaging in G+/Ph2 individuals revealed subclinical systolic
dysfunction in DCM and subtle diastolic abnormalities in HCM.68
LV twist, defined as the wringing motion of the heart caused by the
clockwise rotation of the base and the counterclockwise rotation of
the apex, has an important role in ejection and filling. Twist results
from the interaction of muscle fibres in the right-handed subendocardial
and left-handed subepicardial helices. Peak systolic twist is increased in
HCM patients, likely due to ischaemia of the subendocardial helix. Con-
versely, untwisting is delayed. In DCM, LV twist is reduced due to
impaired apical counterclockwise rotation. In LVNC, the LV base and
apex rotate in the same direction. This ‘solid body rotation’ behaviour
is probably caused by incomplete formation of the subendocardial
helix and is supportive of the diagnosis of LVNC.69
6. Insights fromMRI
The value of MRI in the management of cardiomyopathies relies on
detailed evaluation of heart morphology, function, perfusion, and char-
acterisation of myocardial texture. The latter, unique to MRI, is based on
the capability of identifying various pathological processes affecting the
myocardium, including oedema (associated with acute myocardial
injury and inflammation), fat, fibrosis, haemorrhage, and iron or protein
deposition (Table 2). Magnetic resonance spectroscopy also provides
unique information on cardiac metabolism, although currently restricted
to research applications.70
6.1 Morphology
Morphological features including chamber volumes, ventricular mass,
and spatial distribution of hypertrophy can be accurately assessed by
MRI.The technique is more sensitive thanechocardiography indetecting
hypertrophy in the apical and lateral wall, thus increasing the diagnostic
yield inpatientswith a suspicionofHCM.13 Furthermore, MRIhashelped
unravel additional features of the disease such as crypts, apical aneur-
ysms, and mitral valve abnormalities. In HCM patients, anterior mitral
valve leaflets are considerably longer than those of healthy controls, ir-
respective of age and extent of hypertrophy, predisposing to dynamic
obstruction.71 In .80% of G+/Ph2 individuals from HCM families,
MRI identified profound crypts in the basal and mid-segments of the
inferoseptal myocardium. These crypts may represent the precursor
stage of a disease process ultimately leading to focal hypertrophy.72
The same considerations apply to LV apical-basal muscle bundles.73
Due to its high spatial resolution, MRI allows detailed visualization of
LV trabeculations and represents the gold standard to the diagnosis of
LVNC. However, as previously discussed, the proposed diagnostic cri-
teria for LVNC lack specificity and are often met in patients with
other cardiomyopathies or normal individuals.74
6.2 Function
MRI tomographically defines the LV and therefore provides actual quan-
tification of volumes, relevant to the functional assessment of hypoki-
netic forms such as DCM, LVNC, and end-stage HCM, with greater
accuracy compared with echocardiography. In addition, specific infor-
mation on intramyocardial deformation can be obtained by MRI using
tissue tagging.70 HCM is characterized by contractile heterogeneity of
the LV and depressed systolic deformation, not only in regions with
LGE reflecting scarring or excess interstitial collagen deposition, but
also in the coreof apparently healthy hypertrophic segments.75 This sug-
gests different and as yet unknown mechanisms contributing to regional
systolic dysfunction in HCM. Furthermore, tagging techniques allow the
identification of subclinical LV dysfunction in G+/Ph2, such as subtle
diastolic abnormalities and increased LV torsion,76 the latter thought
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to reflect early subendocardial dysfunction. In patients with DCM, MRI
allows precise quantification of chamber dilatation and dysfunction for
both ventricles, including the possibility of measuring right ventricular
ejection fraction and detailed analysis of regional LV systolic function;
cine MRI is the gold standard for assessing myocardial wall motion and
thickening patterns and has potential in the assessment of ventricular
dyssynchrony.77,78
6.3 Tissue characterization
The characterization of myocardial tissue allowed by MRI has a signifi-
cant value in determining disease progression in cardiomyopathies. In
HCM patients, LGE techniques identify patchy mid-wall enhancement
in 50–80%, correlating positively with regional wall thickness, and in-
versely with wall thickening and LVEF.79 LGE reflects are largely believed
to represent replacement fibrosis. Thus, serial quantitative evaluation of
LGE allows monitoring of disease progression in HCM, generally paral-
leled by worsening functional status (Figure 4). In patients who are
asymptomatic oronly mildly symptomatic, LGE represents an independ-
ent predictor of all-cause and cardiac mortality. When extensive (.20%
of the whole LV), LGE is an independent predictor of sudden cardiac
death.80 In patients with DCM, LGE distribution has a very important
role in excluding an ischaemic origin secondary to epicardial coronary
disease (characterized by subendocardial or transmural distribution of
fibrosis along a well-defined particular coronary arterial territory) or
post-myocarditis DCM.77 Patients with non-ischaemic DCM may
show linear or patchy mid-wall enhancement, which generally represent
the feature of post-myocarditic disease in which ventricular dilatation is
the consequence of the direct damage of the cardiomyocytes by the
aetiological agent. In addition, LGE may involve the subepicardial part
of the myocardium and the right ventricle as well, and importantly it
does not respect a perfusion territory.81 However, patients with familial
DCM generally lack areas of LGE, possibly due to the fact that fibrosis is
mostly diffuse, i.e. interstitial. Myocardial T1 mapping techniques are
promising in this context and may allow the identification and quantifica-
tion of interstitial fibrosis, without the need for a contrast agent.62 This is
due to the fact thatdiffuse collagendeposition increases theextracellular
space, causing an increased interstitial accumulation of gadolinium at
steady state, thus reducing myocardial T1 relaxation time.77 Thus, in
the absence of other active processes, such as oedema, native T1
mapping reflects interstitial fibrosis, which can be assessed as part of
disease development and progression, complementary to the focal re-
placement fibrosis detected by LGE. Several groups have reported in
DCM patients a tight relation between the expansion in extracellular
space (reflecting myocardial fibrosis) and the impairment in myocardial
blood flow (MBF), ventricular dilatation, and ventricular dysfunction.77
Finally, through high signal intensity, T2-weighted MRI emphasizes a pro-
longation of the transverse relaxation time T2, associated with increased
water content of the myocardium, as can be observed in acute ischaemic
and inflammatory disease.69 Focal high T2 signal intensity has been
observed in 33% of patients with HCM, colocalizing with severe LVH
and LGE. Since acute focal ischaemia is a frequent autopsy finding in
HCM,high T2 signal intensity may be acorrelateof microvascular ischae-
mia. To date, however, the exact meaning and reliability of native T1 and
T2 mapping remain controversial.82
6.4 Myocardial perfusion
Myocardial perfusion by MRI is derived from first-pass contrast-
enhanced signal intensity vs. time curves. The technique is semi-
quantitative; however, quantitative MBF in mL/min/g can be calculated
using deconvolution modelling. In HCM patients, adenosine-induced
hyperaemic MBF is blunted in proportion to the magnitude of
hypertrophy,83 thus reproducing the main findings of the earlier
studies based on positron emission tomography (PET). Of note,
reduced maximal coronary flow is associated with regional LV contract-
ile abnormalities, as assessed by MRI tissue tagging, independent of
LGE. However, in the presence of LGE, perfusion abnormalities and
LV dysfunction are more severe.83
7. Insights from PET
Imaging with PET offers unique opportunities for research into tissue
perfusion, biochemical pathways, and pharmacological mechanisms
in vivo. This is made possible by the high sensitivity of PET imaging, enab-
ling the measurement of radiolabelled tracers in concentrations suffi-
ciently low so as not to disturb the processes under study, and the
ability of current scanners to perform rapid dynamic imaging and
provide good temporal resolution.84
7.1 Myocardial blood flow
PET allows reproducible measurements of regional MBF (i.e. tissue per-
fusion in ml/min/g of tissue) providing pathophysiological and diagnostic
information on the function of the coronary macro- and microcircula-
tion. Oxygen-15 labelled water, nitrogen-13 labelled ammonia, and,
more recently, generator-produced rubidium-82 are the tracers that
have been validated in animals against the radiolabelled microsphere
method.84 In the past two decades, studies where coronary flow
reserve was measured in patients with cardiomyopathies and normal
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Summary of MRI techniques applied to image
different heart conditions
MRI techniques Heart condition imaged
Multislice spin-echo Morphology of the myocardium and
fat, blood predominantly dark
Multislice SSFP (Steady-State
Free Precession)
Morphology of vascular
compartments with blood
predominantly bright
Cine SSFPWith tissue tagging Functional imaging of wall motion,
assessment of volumes, and
ejection fraction
Myocardial deformation, strain,
torsion
First-pass contrast-enhancement
with pharmacological stressor
Myocardial perfusion
Myocardial ischaemia
T1-weighted Fat tissue: pericardial, lipomatous
metaplasia in myocardial scar
T2-weighted Myocardial oedema associated with
inflammation or acute myocardial
infarction
T2-star (T2*) Myocardial iron deposition
Late gadolinium enhancement Focal replacement fibrosis (scar)
In acute infarction: area of necrosis
Native T1-mapping Myocardial disease involving
myocyte+interstitium
T1-mapping with use of
extracellular contrast agent
Extra Cellular Volume fraction (ECV),
interstitium, diffuse fibrosis
I. Olivotto et al.418
by guest on M
arch 14, 2015
D
ow
nloaded from
 
coronary angiograms have led to the concept of coronary microvascular
dysfunction85 (Table 3).
In HCM patients, microvascular function and coronary reserve are
blunted diffusely, i.e. both in the hypertrophied and non-hypertrophied
regions of the LV. Furthermore, HCM patients with sarcomere muta-
tions are characterized by greater impairment of flow and prevalence
of LGE, compared with genotype-negative patients, suggesting the
genetic regulation of arteriolar remodelling.86 This finding is consistent
with the higher prevalence of end-stage progression among genotyped
individuals.87 Coronary microvascular dysfunction has been demon-
strated also in patients with other cardiomyopathies, including DCM,
LVNC, and Anderson Fabry disease. Both in HCM and DCM, the
degree of microvascular dysfunction is an independent predictor of
cardiac events and progression of heart failure.88,89 These findings
support the hypothesis that microvascular ischaemia might represent
a common pathway leading to disease progression in different cardiomy-
opathies and support the use of non-invasive imaging with PET for risk
stratification. Finally, microvascular dysfunction represents an obvious
therapeutic target in patients with cardiomyopathies, aimed at im-
proving perfusion and preventing adverse LV remodelling.90 Because a
blunted perfusion reserve precedes the development of myocardial
fibrosis and systolic dysfunction by years, early identification of micro-
vascular flow abnormalities represents an opportunity for pharmaco-
logical prevention of disease progression.
7.2 Autonomic dysfunction
In studies using11C-CGP 12177, a non-selective b-adrenoceptor antag-
onist enabling the study of the functional receptor pool on the cell
surface, patients with HCM have shown diffuse down-regulation of myo-
cardial b-adrenoceptors, correlated to the degree of LV dysfunction.91
Furthermore, a PET study with 11C-labelled hydroxyephedrine has
demonstrated significant impairment of transporter-mediated neuronal
uptake at the pre-synaptic level in HCM. The net effect is an increased
concentration of catecholamine in the synaptic cleft which in turn
might contribute to b-adrenoceptor down-regulation.91 Of note,
these abnormalities may actually ‘precede’ the onset of LV dysfunction
and thus play a role in its genesis, rather than represent an epiphenom-
enon. Further studies are warranted to understand whether this mech-
anism may represent a viable therapeutic target.91
8. Role of circulating biomarkers
Biomarkers provide clinically useful information, complementary to
imaging, aiding clinicians in the evaluation of haemodynamic com-
pensation, microvascular ischaemia, inflammatory status, and collagen
turnover. In addition, biomarkers may predict disease progression and
outcome in a variety of cardiac conditions including cardiomyopathies.
8.1 Hypertrophic cardiomyopathy
8.1.1 Troponins and brain natriuretic peptides
In 2003, Sato et al.92 provided the first report of increased cardiac tropo-
nin T (cTnT) levels in HCM patients, in whom reduced fractional short-
ening was noted during follow-up. Similar findings were later described
for cardiac troponin I (cTnI) and high-sensitivity cardiac troponin T
(hs-cTnT), supporting the idea that acute subclinical ischaemia is rele-
vant to adverse LV remodelling and dysfunction. Indeed, hs-cTnT
levels.14 ng/L represented strong and independent predictors of car-
diovascular events in HCM patients in one study.93 Furthermore,
increased hs-cTnT values were associated with the presence of replace-
ment fibrosis assessed by LGE.93 Overall, these results suggest a poten-
tial utilityof troponin dosage in the evaluationof disease progressionand
response to treatment. Adverse LV remodelling is coupled with changes
in ventricular stretch, accounting for increased circulating levels of the
N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) in
HCM patients, in whom a correlation has been reported between
plasma NT-proBNP values and several indexes of LV remodelling and
dysfunction. A prospective study enrolled 183 stable outpatients with
HCM, largely asymptomatic or mildly symptomatic, followed-up for 4
years: plasma levels of NT-proBNP were found to be powerful and inde-
pendent predictors of heart failure-related events.94 Similar resultswere
reported by Coats et al.,95 who evaluated 847 HCM patients for an
average of 3.5 years: baseline NT-proBNP values were associated with
symptomatic progression, reduced LVEF and all-cause mortality or
cardiac transplantation. Of note, the additive and independent prognos-
tic relevance of hs-cTnT and NT-proBNP is emerging. If confirmed by
larger studies, these findings will have direct applications in current clin-
ical practice for risk stratification and therapeutic decision-making in
HCM patients.94,95
8.1.2 Novel biomarkers
HCM patients exhibit higher levels of interleukin-6, compared with con-
trols, even when inflammatory conditions are excluded,96 possibly as a
response to abnormal LV contraction. A vicious circle has therefore
been proposed in HCM pathogenesis, by which LV hypertrophy pro-
motes interleukin-6 release, in turn promoting further hypertrophy.
Similarly, increased levels of pro-apoptotic molecules such as tumour
necrosis-a and soluble Fas ligand havegenerated the hypothesis that car-
diomyocyte apoptosis might play a decisive role in promoting fibrosis
and disease progression in HCM patients.96 Indeed, marked increases
in tumour necrosis-a have been reported in the end-stage phase of
HCM.97 Both interleukin-6 and tumour necrosis-apromote the expres-
sion of matrix metalloproteinases (MMPs), which have been related to
cardiac remodelling and fibrosis in heart disease, including DCM.98
Several MMPs are increased in the serum of HCM patients, such as
MMP-9 and MMP-3, respectively associated with LGE and increased ar-
rhythmic risk.98 Aldosterone, known to promote MMP expression, is
frequently elevated in HCM patients and has been repeatedly identified
as a potential therapeutic target. Finally, the role of micro-RNAs as key
regulators of gene expression is receiving increasing attention in cardio-
vascular disease.99 In HCM patients, of several up-regulated micro-
RNAs, only the circulating levels of miR-29a were found to correlate
with both myocardial hypertrophy and fibrosis, suggesting common
molecular pathways for these two features.99
8.2 Dilated cardiomyopathy
Increased hs-cTnT levels represent independent predictors of
cardiac death in DCM. In addition, increased NT-proBNP levels are
associated with adverse LV remodelling and functional deterioration
and predict adverse outcome in children with DCM.100 In contrast,
lower plasma levels of BNP predict reverse remodelling in response
to treatment.101 Galectin-3 levels have not yet been shown to have a
predictive role in DCM patients.100 However, both galectin-3 and
ST2 are emerging as biomarkers of myocardial fibrosis, and strong
outcome predictors in chronic heart failure patients, and deserve to
be properly evaluated in DCM. Finally, creatine kinase should routinely
be evaluated in DCM patients in relation to its diagnostic utility for
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lamin A/C cardiomyopathy and other forms of DCM with skeletal
muscle involvement.8
9. Investigations and follow-up
of phenotype-negative individuals
The availability of genetic testing in clinical practice has led to the iden-
tification of large G+/Ph2 cohorts in families with HCM, DCM, and
LVNC. The exact proportion of G+/Ph2 subjects that develop
overt disease is currently unknown. Penetrance of fully expressed
phenotype increases with age, but is incomplete, in both children
and adults, and an evident phenotype may be absent even at an
advanced age.81 In HCM, the reported risk of adverse cardiac events
in G+/Ph2 is very low, and no sudden deaths were reported in the
largest cohort reported to date.102 According to current HCM guide-
lines, G+/Ph2 children and adolescents should be evaluated by ECG
and TTE at intervals of 1–2, whereas adults only every 2–5 years.9
There are no specific guidelines for the other sarcomeric cardiomyop-
athies, although there is consensus that all G+/Ph2 should be evalu-
ated at regular intervals.
In HCM, ECG abnormalities can be present before LV hypertrophy
develops, and their severity is related to the degree of LV hypertrophy
and LGE on MRI.54 The ECG is therefore a sensitive screening tool,
and the one with the highest cost–benefit ratio. In G+/Ph2 subjects,
subtle changes can be found by TTE, not fulfilling diagnostic criteria
for a specific cardiomyopathy. Criteria combining ECG and TTE data,
including mitral valve or papillary muscle abnormalities, have been
proposed to diagnose HCM. Tissue Doppler imaging studies in G+/
LVH2 subjects have consistently revealed subtle evidence of diastolic
dysfunction.103 In G+/Ph2 subjects from DCM families, mild- LV en-
largement and subtle abnormalities in systolic function are common,
representing markers of pre-clinical disease. MRI is a valuable adjunct
in the cardiac evaluation of G+/Ph2 subjects, especially when TTE
images are suboptimal. As an example, MRI can detect mild- LV hyper-
trophy inup to10%of mutationcarrierswith negativeTTE.72 Myocardial
crypts, diastolic abnormalities, and increased LV torsion have been
identified by MRI in G+/Ph2 subjects and represent pre-phenotypic
features of HCM.104 Although LGE is extremely rare in G+/Ph2 sub-
jects, they often exhibit increased extracellular volume and circulating
end-products of collagen synthesis, such as the C-terminal propeptide
of type I procollagen, supporting the concept of fibrotic remodelling oc-
curring very early during disease development.105
10. Conclusions
The long-term care of patients with sarcomeric cardiomyopathies is
largely based on a ‘low-tech, high-touch’ approach aimed at providing
clinical stabilityover decades and preserving quality of life. Technological
innovations such as the implantable defibrillator, contemporary surgical
techniques, ventricular assist devices, and transplantation are reserved
to a minority of patients, whereas standard medical therapy and lifestyle
modifications areoften sufficient in most. Irrespectiveof clinical severity,
evaluation and follow-up by a dedicated, multidisciplinary team is of crit-
ical importance in order to establish the correct diagnosis, provide re-
assurance when appropriate, understand causes of deterioration, and
identify high-risk patients. Instrumental evaluations lose their meaning
unless theyare oriented towards and followedbya comprehensive, inte-
grated interpretation of findings in the hands of clinicians. Ongoing re-
search is pursuing the ambitious aim of developing disease-specific
therapies targeting pathophysiological aspects of sarcomere-related
disease: a state-of-the-art multimodality assessment offers the best op-
portunities to achieve such aim, by identifying of clinical targets, charac-
terizing patient subsets for randomized trials, defining viable study
end-points, and evaluating the effects of treatment over time.
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